ArticleScientific reports2026
Integrative transcriptomic and machine learning analysis identifies key extracellular matrix-related genes in diabetic retinopathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Extracellular matrix (ECM) remodeling contributes to retinal vascular basement membrane thickening, an early structural hallmark of diabetic retinopathy (DR). This study aimed to identify key ECM-related genes (ECMGs) associated with DR. Transcriptomic data of DR and ECMGs from MatrixDB were integrated to identify differentially expressed ECMGs. Six machine learning (ML) models, including Extra Trees (ET), Logistic Regression, Adaptive Boosting, Random Forest, Extreme Gradient Boosting, and naive Bayes classifier, were employed to construct DR classification models, with SHapley Additive exPlanation (SHAP) used to interpret feature contributions. Functional enrichment analysis using GSEA and immune infiltration analysis using CIBERSORT were conducted to explore the potential mechanisms by which key ECMGs regulate DR. Regulatory networks were constructed using predicted miRNAs, lncRNAs, and transcription factors (TFs) via the ENCORI, miRWalk, and miRNet databases. Drug-key ECMGs-DM-related diseases interactions were further explored using the DGIdb and CTD databases. Nine candidate ECMGs were identified by overlapping 356 DM-associated DEGs, 1,626 DR-associated DEGs, and 1,023 ECMGs, including CILP2, FN1, DEFA3, COL17A1, CRISP3, TPSAB1, SFRP1, GPHA2, and ECM2. Among the six ML algorithms, the ET classifier exhibited the best overall performance, and five ECMGs (SFRP1, CILP2, FN1, TPSAB1, and ECM2) with non-zero SHAP values were retained as key genes. These genes showed distinct expression patterns across the healthy, DM, and DR groups, and were enriched in neural-related pathways, such as axon guidance, glycosphingolipid biosynthesis ganglio series, and neuroactive ligand receptor interaction. Immune profiling and correlation analysis revealed that FN1, TPSAB1, and CILP2 were correlated with memory/naive B cells, CD8 + T cells, activated memory CD4 + T cells, Tregs, monocytes, and neutrophils. Additionally, the ceRNA network contained five miRNAs, 7 lncRNAs, and two ECMGs, and further regulatory and pharmacologic analysis further linked key ECMGs to specific TFs, drugs, and diabetes-related diseases. This study identified SFRP1, CILP2, FN1, TPSAB1, and ECM2 as key ECMGs in DR, revealing their coordinated involvement in ECM remodeling, neural signaling, and immune modulation. These findings provide novel insights into DR pathogenesis and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.